International Guest Seminar with Steven E Hyman "A decade’s journey from psychiatric genetics to mechanisms and biomarkers — and the hard problems that remain"

Short biography

Steven E. Hyman, MD, is a Core Institute Member of the Broad Institute of MIT and Harvard and Director of the Broad Program in Brain Health. He is also Harvard University Distinguished Service Professor and Harald McPike Professor of Stem Cell and Regenerative Biology.

In 2024 Hyman became the first director of the Program in Brain Health at the Broad Institute, supporting translational research on brain disorders. From 2012-2024, he directed the Broad’s Stanley Center for Psychiatric Research. He is principal investigator of the Psychiatric Biomarkers Network, a multi-institutional and multi-sector collaboration focused on fluid biomarkers for the schizophrenia spectrum and bipolar disorder. From 2001 to 2011 Hyman served as Provost (chief academic officer) of Harvard University. From 1996 to 2001 he was Director of the US National Institute of Mental Health (NIMH), where he invested in neuroscience and emerging genomic technologies and initiated a series of large clinical trials to inform practice. He has served as Editor of the Annual Review of Neuroscience (2002-2016), founding President of the International Neuroethics Society (2008-2013), President of the Society for Neuroscience (2015), and President of the American College of Neuropsychopharmacology (2018). He is a fellow of the American Academy of Arts and Sciences, a fellow of the American Association for the Advancement of Science, a distinguished life fellow of the American Psychiatric Association, and a member of the National Academy of Medicine (NAM) where he chaired the Forum on Neuroscience and Nervous System Disorders (2012-2018). He chairs the Boards of Directors of the Charles A. Dana Foundation (NY) and the Wyss Center for Bio and Neuroengineering (Geneva, Switzerland). In the private sector he is a Director of Voyager Therapeutics, Cyclerion Therapeutics, and Vesalius Therapeutics. He serves on the Scientific Advisory Boards of J&J Innovative Medicine and F-Prime Capital. He received his BA, summa cum laude, from Yale, an MA from the University of Cambridge, which he attended as a Mellon fellow studying History and Philosophy of Science, and an MD, cum laude, from Harvard Medical School.